5 Key Takeaways

• 1

  Companion diagnostics are essential for precision medicine, identifying patients likely to respond to specific therapies.

• 2

  AstraZeneca has approved over sixty-five companion diagnostics in oncology since 2014, emphasizing their importance in treatment decisions.

• 3

  AI and computer vision are enhancing companion diagnostics, allowing for more personalized disease segmentation and treatment tailoring.

• 4

  Barriers to widespread companion diagnostics include infrastructure inconsistencies, speed of innovation translation, and data processing challenges.

• 5

  Collaborations among diagnostic companies, pharma, and healthcare providers are crucial for overcoming barriers and improving patient access to precision medicine.